Quotient Therapeutics, a company pioneering somatic genomics to inform breakthrough medicines, announced that it has entered a multi-year research collaboration agreement with MSD (tradename of Merck & Co., Inc., Rahway, N.J., USA), to discover novel drug targets in inflammatory bowel disease (IBD) using Quotient’s somatic genomics platform technology.
